CN117736902A - Probiotic composition and application thereof - Google Patents
Probiotic composition and application thereof Download PDFInfo
- Publication number
- CN117736902A CN117736902A CN202311419265.0A CN202311419265A CN117736902A CN 117736902 A CN117736902 A CN 117736902A CN 202311419265 A CN202311419265 A CN 202311419265A CN 117736902 A CN117736902 A CN 117736902A
- Authority
- CN
- China
- Prior art keywords
- cgmcc
- preservation number
- lactobacillus
- probiotic
- probiotic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 73
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 73
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000004321 preservation Methods 0.000 claims abstract description 44
- 230000000968 intestinal effect Effects 0.000 claims abstract description 25
- 230000036541 health Effects 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 14
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 13
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 13
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 13
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 13
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 13
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 13
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 13
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 13
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 13
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 12
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 12
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 27
- 235000015141 kefir Nutrition 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 239000002577 cryoprotective agent Substances 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 29
- 238000012360 testing method Methods 0.000 description 20
- 229920001817 Agar Polymers 0.000 description 13
- 241000186660 Lactobacillus Species 0.000 description 13
- 239000008272 agar Substances 0.000 description 13
- 229940039696 lactobacillus Drugs 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 235000013339 cereals Nutrition 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000012216 screening Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 238000009629 microbiological culture Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 238000003794 Gram staining Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 230000009974 thixotropic effect Effects 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 4
- 229940107187 fructooligosaccharide Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 244000005709 gut microbiome Species 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 208000028774 intestinal disease Diseases 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 150000001945 cysteines Chemical class 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000008991 intestinal motility Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229920002558 Curdlan Polymers 0.000 description 2
- 239000001879 Curdlan Substances 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 241000227653 Lycopersicon Species 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000009193 crawling Effects 0.000 description 2
- 229940078035 curdlan Drugs 0.000 description 2
- 235000019316 curdlan Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a probiotic composition and application thereof. The composition comprises bifidobacterium longum BL986 with the preservation number of CGMCC No.18743, lactobacillus acidophilus LA1063 with the preservation number of CGMCC No.18744, lactobacillus fermentum LF26 with the preservation number of CGMCC No.19431, lactobacillus helveticus LH43 with the preservation number of CGMCC No.24511, lactobacillus paracasei LPC12 with the preservation number of CGMCC No.24512, lactobacillus rhamnosus LRH10 with the preservation number of CGMCC No.24513 and streptococcus thermophilus ST30 with the preservation number of CGMCC No.24514. The method can obviously improve the yoga intervention or auxiliary treatment effect in the process of the yoga intervention for intestinal dryness, so that the method can be used for preparing medicines, foods or health care products for improving the intestinal dryness.
Description
Technical Field
The invention belongs to the technical field of probiotics, and particularly relates to a probiotic composition and application thereof.
Background
Intestinal dryness (IBS) is a common functional intestinal disorder with a prevalence of 10-20%. It is characterized in that abdominal pain or cramps are accompanied by intestinal dysfunction, including flatulence, diarrhea or constipation. Patients with IBS are often associated with depression or bipolar disorder. It has long been considered a psychological and psychiatric disorder, not a mere physical disorder. Clinically, anti-depressants are often used to treat IBS, as well as drugs that promote or inhibit intestinal motility. However, these drugs are often accompanied by strong side effects, not only causing discomfort to the patient, but also placing more demands on medical resources.
Early researchers thought that symptoms of intestinal dryness (IBS) were mainly due to abnormal intestinal motility. The contraction of the intestinal smooth muscle is too strong or long in duration, resulting in a transfer disorder, causing the patient to feel abdominal pain and discomfort (Fraser, 2001). In about 25% to 75% of IBS patients, the frequency of contraction and rate of delivery of each segment of the intestine is indeed different from that of the healthy control group, while the volume elasticity of the intestine is the same as that of the healthy control group. IBS can therefore be regarded as a functional bowel disorder lacking physiological structure or abnormal patterns of bowel movement (Drossman et al, 2002).
In addition to dietary and pharmaceutical treatments, probiotics have been shown to be effective in preventing and ameliorating many diseases in recent years without strong side effects. Probiotics have been shown to improve the efficacy of many intestinal diseases by increasing the intestinal mucosal barrier function, activating the host immune system and maintaining the intestinal microbiota. The probiotics can reduce the occurrence of intestinal infection or inflammation, thereby preventing intestinal diseases. Recent studies indicate that probiotics not only have an immunomodulatory effect on the host, but also regulate the metabolic rate of the host, converting tryptophan to serotonin to alleviate depression. Serotonin is closely related to the activation of the enteric nervous system. The oral probiotics can improve the diversity and the richness of intestinal microorganisms, and further become an auxiliary treatment means for improving the symptoms of intestinal dryness (IBS).
The intestinal tract of adults has more than 500 microbial flora, including 18 major species. The normal intestinal microbiota can reduce the growth of pathogenic bacteria, regulate intestinal immune response and maintain intestinal balance. Current epidemiological, biological and clinical studies indicate that changes in the quality or quantity of the intestinal microbiota may be related to the occurrence of IBS. Intestinal infections may alter the original microbial flora. Epidemiological data have found that IBS occurs at about 6-31% after infectious enteritis. Overgrowth of enterobacteriaceae, coliform and antagonistic bacteria occurs in the intestinal tract of IBS patients and lactic acid bacteria and bifidobacteria are reduced compared to healthy persons. Overgrowth of intestinal bacteria can ferment carbohydrates, producing excess carbon dioxide, hydrogen and methane, causing abdominal distension and gas discharge.
Recently researchers have proposed the concept of the Gut-Muscle Axis (glut-Muscle Axis), which is thought that microorganisms in the Gut may affect protein synthesis and metabolism, and thus Muscle growth (tisini et al, 2017). From another point of view, the maintenance of the muscles depends on proper exercise training. In recent years, some researchers have also suggested that exercise may alter the flora and microbial metabolites in the gut, thereby reducing the risk of chronic diseases. The study by Clarke et al showed that the sporter had a richer intestinal microbiota. Furthermore, past studies have shown that interventions in exercise and physical activity can reduce chronic inflammation (Clarke et al, 2014). Neuroscientists also consider motor as an independent risk factor for brain cognitive function, but whether motor can be used to modulate the gut flora and thus affect health factors, especially in IBS patients, still need to be explored further.
Currently, popular exercise is also one of the main means, in which yoga is used as a comprehensive exercise mode, and various systems of the body including a nervous system, an endocrine system, an immune system and the like can be regulated, but yoga also has the following disadvantages: the applicability is poor: not all people can alleviate intestinal dryness through yoga, and the effect is unstable: the therapeutic effects of yoga may vary from person to person.
At present, probiotics are mainly used as auxiliary means for treating intestinal dryness by simply combining single probiotics or several probiotics strains with similar functions, and the combined probiotics do not take the mutual influence among the strains into consideration, in particular to achieve the interaction among the probiotics supplemented in intestinal tracts.
Disclosure of Invention
The invention aims to: the invention aims to provide a probiotic composition for improving symptoms of intestinal dryness (IBS) and application thereof.
The technical scheme is as follows: the aim of the invention is achieved by the following technical scheme:
the invention provides a probiotic composition, which comprises bifidobacterium longum BL986 with the preservation number of CGMCC No.18743, lactobacillus acidophilus LA1063 with the preservation number of CGMCC No.18744, lactobacillus fermentum LF26 with the preservation number of CGMCC No.19431, lactobacillus helveticus LH43 with the preservation number of CGMCC No.24511, lactobacillus paracasei LPC12 with the preservation number of CGMCC No.24512, lactobacillus rhamnosus LRH10 with the preservation number of CGMCC No.24513 and streptococcus thermophilus ST30 with the preservation number of CGMCC No. 24514;
the ratio of the bacterial numbers of each bacterial strain in the probiotic composition is as follows:
biological material preservation information:
bifidobacterium longum (Bifidobacterium longum) BL986, which has been preserved in China general microbiological culture Collection center (China center for type culture Collection) on 10 and 28 days in 2019, wherein the preservation address is 1 to 3 in North Chenxi Lu of the Chaoyang area of Beijing, and the preservation number is 18743 CGMCC;
lactobacillus acidophilus (Lactobacillus acidophilus) LA1063, which is preserved in China general microbiological culture Collection center (China center for type culture Collection) at the date of 10 and 28 in 2019, wherein the preservation address is the North Chen Xili No.1, 3 in the Guangyang area of Beijing, and the preservation number is CGMCC No.18744;
lactobacillus fermentum (Limosilactobacillus fermentum) LF26 is preserved in China general microbiological culture Collection center (China center for type culture Collection) for 24 days in 2 months of 2020, wherein the preservation address is 1 # 3 of North Chen West Lu in the Korean area of Beijing, and the preservation number is CGMCC No.19431;
lactobacillus helveticus (Lactobacillus helveticus) LH43, which is preserved in China general microbiological culture Collection center (China center for type culture Collection) on 3/11 of 2022, wherein the preservation address is 1/3 of North Xielu in the Korean area of Beijing, and the preservation number is CGMCC NO.24511;
lactobacillus paracasei (Lacticaseibacillus paracasei) LPC12, which has been preserved in China general microbiological culture Collection center (China center for type culture Collection) for 3 months and 11 days, wherein the preservation address is 1 # 3 of North Chen Silu No.1 in the Korean area of Beijing, and the preservation number is CGMCC No.24512;
lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) LRH10, which is preserved in China general microbiological culture Collection center (China center for type culture Collection) on 3/11 of 2022, wherein the preservation address is 1/3 of North Chenxi Lu in the Korean area of Beijing, and the preservation number is CGMCC NO.24513;
streptococcus thermophilus (Streptococcus thermophilus) ST30 is preserved in China general microbiological culture Collection center (China center for type culture Collection) at the 3 rd month 11 of 2022, and the preservation address is the 1 ST national standard number 3 of North Chen West Lu of the Korean area of Beijing city, and the preservation number is CGMCC NO.24514.
Preferably, the viable count of the composition is not less than 1.5X10 10 CFU/g。
The invention also provides application of the probiotic composition in preparation of medicines for improving intestinal dryness.
The medicament comprises the probiotic composition and a pharmaceutically acceptable carrier or auxiliary material.
The auxiliary materials comprise one or more of preservative, antioxidant, emulsifier, wetting agent, diluent, disintegrating agent or adhesive.
The medicaments of the present invention may be administered in a variety of known ways, such as orally, by injection, etc. The medicine of the invention can be used alone or in combination with other medicines. The oral composition may be any orally acceptable dosage form including, but not limited to, tablets, granules, capsules, pills, suspensions, and solutions.
The actual dosage level of the active ingredient in the medicament of the present invention may be varied to obtain an amount of active ingredient that is effective to achieve the desired therapeutic response for the particular patient, composition and mode of administration, which is non-toxic to the patient. The selected dosage level depends on a variety of factors including the route of administration, the time of administration, the rate of excretion, the duration of the treatment, other drugs, compounds and/or materials used in combination with the probiotic composition, the age, sex, weight, general health and past medical history of the patient being treated, and like factors well known in the medical arts.
The invention also provides application of the probiotic composition in preparing food or health care products for improving intestinal dryness.
The probiotic composition can be added into foods and health care products for oral administration. Can also be combined with other beverage materials to make into beverage products such as carbonated beverage, fruit juice beverage, lactobacillus beverage, sports beverage, etc. The food for improving intestinal dryness can also be made into daily foods such as biscuits, candies, bread, desserts and the like.
According to the research of the invention, the effect of yoga intervention or auxiliary treatment can be obviously improved in the process of performing intestinal dryness intervention on the yoga.
The invention also provides probiotic powder, which comprises the probiotic composition. In the actual production process, the inventor prepares Cheng Yi probiotic powder from the probiotic composition for subsequent application. For the preparation of the probiotic powder, the conventional technical means in the field are adopted. In the embodiment of the invention, the probiotic powder is obtained by mixing freeze-dried powder of each strain in proportion.
The preparation method of the probiotics comprises the following steps: separating each strain in the probiotic composition from Taiwan natural dairy kefir grains, preparing freeze-dried powder of each strain by a freeze-drying method, and preparing the probiotic powder by the freeze-dried powder of each strain according to a proportion.
The freeze drying method is to use maltodextrin and fructo-oligosaccharide as cryoprotectants and then freeze-dry.
The invention also provides an AB kefir capsule which is prepared from the probiotic powder and a pharmaceutically acceptable carrier or excipient. For the preparation of the AB kefir capsules, common pharmaceutically acceptable carriers or excipients are used. Such commonly used pharmaceutically acceptable carriers or excipients include stabilizers, surfactants, lubricants, antioxidants, binders, colorants, fillers, and the like. In the embodiment of the invention, the probiotic powder is prepared into a capsule dosage form (each granule has the main component of probiotic composition of 1.5 multiplied by 10 10 CFU/granule) for pharmacodynamic tests.
The beneficial effects are that:
(1) The invention combines probiotics separated and screened from homologous Kefir, the compounding method can increase the diversity of strains, and compared with common simple combined probiotics, the invention has the characteristics of natural strong adaptability and strong survivability.
(2) The probiotic composition provided by the invention can be used for obtaining more comprehensive nutrition supplement through compounding, and better meets the health requirements of human bodies. Experiments show that the probiotic composition can be used for preparing medicines, foods or health care products for improving intestinal dryness.
(3) The probiotic composition provided by the invention is used for improving the effect of yoga intervention or auxiliary treatment obviously in the process of performing intestinal dryness intervention by using yoga.
Detailed Description
The technical scheme of the present invention is described in detail below through specific examples, but the scope of the present invention is not limited to the examples.
The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used were conventional products available for purchase through regular channels, with no manufacturer noted.
The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the examples described below, unless otherwise specified, are all commercially available products.
In the embodiment of the invention, the adopted probiotic bacterial strains are all obtained by separating and preparing Taiwan Kefir grains (Kefic grains).
EXAMPLE 1 cultivation of Lactobacillus acidophilus LA1063, lactobacillus fermentum LF26, lactobacillus helveticus LH43, lactobacillus paracasei LPC12 and Lactobacillus rhamnosus LRH10
(1) Preparation of MRS Medium
The specific components of MRS culture medium are as follows:
the preparation method comprises the following steps: adding the components into 1000mL of distilled water, heating and dissolving, adjusting the pH to 6.2+/-0.2, sub-packaging, and sterilizing at 121 ℃ for 15-20 min under high pressure to obtain the MRS culture medium.
(2) Lactobacillus acidophilus LA1063, lactobacillus fermentum LF26, lactobacillus helveticus LH43, lactobacillus paracasei LPC12 and lactobacillus rhamnosus LRH10 are separated from kefir grains of Taiwan natural dairy products:
a first step of: taking Taiwan natural dairy kefir grains as lactobacillus screening source samples, inoculating the samples into 10wt% skimmed milk powder culture solution, performing colonization culture (Enrichment culture) at 37 ℃ for 18 hours, and screening out strains generating a curdlan phenomenon;
and a second step of: taking a sample after the colony culture, carrying out serial dilution and plate streak culture, and culturing for 3 days under the anaerobic condition at 37 ℃ to respectively select a plurality of single colonies with different bacterial phases;
and a third step of: respectively carrying out gram staining and a thixotropic reaction test on the single bacterial colony, screening a plurality of strains which are positive in gram staining and negative in the thixotropic reaction, namely a plurality of lactobacillus strains which are preliminarily screened, and carrying out identification of strains of the lactobacillus strains which are preliminarily screened, wherein lactobacillus acidophilus, lactobacillus fermentum, lactobacillus helveticus, lactobacillus paracasei and lactobacillus rhamnosus in the lactobacillus strains which are preliminarily screened are respectively identified as lactobacillus acidophilus LA1063, lactobacillus fermentum LF26, lactobacillus helveticus LH43, lactobacillus paracasei LPC12 and lactobacillus rhamnosus LRH10;
(3) Respectively diluting lactobacillus acidophilus LA1063, lactobacillus fermentum LF26, lactobacillus helveticus LH43, lactobacillus paracasei LPC12 and lactobacillus rhamnosus LRH10 with sterile physiological saline;
(4) Each strain was individually selected for 3 dilutions (10 -6 、10 -7 、10 -8 ) Each concentration was placed in 2 MRS agar plates (0.1 mL each) at 0.1mL each, surface-coated with L-bars, and anaerobic cultured at 37℃for 48 hours;
(5) The Lactobacillus acidophilus LA1063, lactobacillus fermentum LF26, lactobacillus helveticus LH43, lactobacillus paracasei LPC12 and Lactobacillus rhamnosus LRH10 were individually inoculated with an inoculating loop to pick colonies on plates (colonies were uniformly distributed on 30-100 plates),respectively inoculating into separate fermentation culture medium (the fermentation culture medium comprises glucose 25g/L, soybean peptone 10g/L, yeast powder 8g/L, K) 2 HPO 4 2g/L，CH 3 COONa 7g/L, sodium citrate 3g/L, mgSO 4 0.2g/L，FeCl 2 0.1g/L，MnSO 4 0.05 g/L), fermenting at 37deg.C for 12 hr; centrifuging to obtain bacterial mud, adding maltodextrin and fructo-oligosaccharide as cryoprotectant, and lyophilizing to obtain lyophilized powder of Lactobacillus acidophilus LA1063, lactobacillus fermentum LF26, lactobacillus helveticus LH43, lactobacillus paracasei LPC12 and Lactobacillus rhamnosus LRH10, respectively.
EXAMPLE 2 cultivation of Bifidobacterium longum BL986
(1) Preparation of Bifidobacterium agar Medium
The bifidobacterium agar medium comprises the following specific components:
preparation of cysteine salt solution: 0.5g of cysteine was weighed, and 1.0mL of hydrochloric acid was added to dissolve all the cysteine, thereby preparing a cysteine salt solution.
Preparation of tomato extract: cleaning fresh tomatoes, weighing and cutting, adding distilled water with the same amount, heating in a water bath at the temperature of 100 ℃, stirring for 90min, filtering with gauze, correcting the pH value to 7.0+/-0.1, subpackaging the leaching solution, and sterilizing at the temperature of 121 ℃ for 15-20 min.
The preparation method comprises the following steps: adding all the components into distilled water, heating for dissolving, adding cysteine salt solution, and correcting pH to 6.8+ -0.1. And (5) sub-packaging, and sterilizing at 121 ℃ for 15-20 min to obtain the bifidobacterium agar culture medium.
(2) Isolation of bifidobacterium longum BL986 from natural Kefir grains:
a first step of: taking Taiwan natural dairy Kefir grains as a lactobacillus screening source sample, inoculating the sample into 10wt% skimmed milk powder culture solution, performing colonization culture (Enrichment culture) at 37 ℃ for 18 hours, and screening out a strain generating a curdling phenomenon;
and a second step of: taking a sample after the colony culture, carrying out serial dilution and plate streak culture, and culturing for 3 days under the anaerobic condition at 37 ℃ to select a plurality of single colonies with different bacterial phases;
and a third step of: respectively carrying out gram staining and thixotropic reaction test on the single bacterial colony, screening out a plurality of strains with positive gram staining and negative thixotropic reaction, namely a plurality of lactobacillus strains which are preliminarily screened, and carrying out strain identification on the lactobacillus strains which are preliminarily screened, wherein bifidobacterium longum in the lactobacillus strains which are preliminarily screened is identified as bifidobacterium longum BL986;
(3) Respectively diluting bifidobacterium longum BL986 with sterile physiological saline;
(4) 3 dilutions were selected for each strain separately (10 -6 、10 -7 、10 -8 ) Each concentration was placed in 0.1mL of 2 plates of bifidobacterium agar medium (0.1 mL each plate) and surface-coated with L-shaped bars, anaerobic cultured at 37 ℃ for 48h;
(5) The bifidobacterium longum BL986 is singly inoculated with an inoculating loop to pick out colonies on a flat plate (the colonies are uniformly distributed and the colonies are picked out on 30-100 flat plates), and the colonies are respectively inoculated into a single fermentation medium (the specific composition of the fermentation medium is that the bifidobacterium agar medium is used for removing agar powder) for high-density culture, and are fermented for 12 hours at the temperature of 37 ℃; and (3) centrifugally separating to obtain bacterial sludge, adding maltodextrin and fructo-oligosaccharide as cryoprotectants, and freeze-drying to obtain bifidobacterium longum BL986 freeze-dried powder.
EXAMPLE 3 cultivation of Streptococcus thermophilus ST30
(1) Preparation of MC Medium
The MC medium comprises the following specific components:
the preparation method comprises the following steps:
adding soybean peptone, beef powder, glucose, lactose, calcium carbonate, and agar into distilled water, heating for dissolving, adjusting pH, and adding 1% neutral red solution. And (3) after sub-packaging, sterilizing at 121 ℃ for 15-20 min to obtain the MC agar culture medium.
(2) Streptococcus thermophilus ST30 is separated from traditional and natural dairy kefir grains of Taiwan China:
a first step of: taking traditional natural milk kefir grains as lactobacillus screening source samples, inoculating the samples into 10wt% of skimmed milk powder culture solution, performing colonization culture (Enrichment culture) at 37 ℃ for 18 hours, and screening out strains generating a curdlan phenomenon;
and a second step of: taking a sample after the colony culture, carrying out serial dilution and plate streak culture, and culturing for 3 days under the anaerobic condition at 37 ℃ to select a plurality of single colonies with different bacterial phases;
and a third step of: respectively carrying out gram staining and thixotropic reaction test on the single bacterial colony, screening out a plurality of strains with positive gram staining and negative thixotropic reaction, namely a plurality of lactobacillus strains which are preliminarily screened, and carrying out strain identification on the lactobacillus strains which are preliminarily screened, wherein streptococcus thermophilus in the lactobacillus strains which are preliminarily screened is identified as streptococcus thermophilus ST30;
(3) Respectively diluting Streptococcus thermophilus ST30 with sterile physiological saline;
(4) 3 dilutions were selected for each strain separately (10 -6 、10 -7 、10 -8 ) Each concentration was placed in 0.1mL of 2 MC agar medium agar plates (0.1 mL each) and surface-coated with L-bars, and anaerobic cultured at 37℃for 48 hours;
(5) The streptococcus thermophilus ST30 is singly picked up by an inoculating loop to form colonies on plates (the colonies are evenly distributed and are picked up on 30-100 plates), and the colonies are respectively inoculated into a single fermentation medium (the specific composition of the fermentation medium is MC agar medium, agar powder is removed) for high-density culture, and are fermented for 12 hours at the temperature of 37 ℃; centrifuging to obtain bacterial mud, adding maltodextrin and fructo-oligosaccharide as cryoprotectant, and lyophilizing to obtain Streptococcus thermophilus ST30 lyophilized powder.
EXAMPLE 4 mixing of probiotic powders
The freeze-dried powders prepared by separating examples 1-3 from kefir were mixed according to the following proportions:
EXAMPLE 5AB kefir capsules (probiotic supplement, 1.5X10 of probiotic composition as the main ingredient) 10 CFU/granule
And (3) taking the mixed probiotic powder in the embodiment 4, and preparing the AB kefir capsule by using a common pharmaceutically acceptable carrier or excipient.
The main strains of each capsule are bifidobacterium longum BL986 with the preservation number of CGMCC No.18743, lactobacillus acidophilus LA1063 with the preservation number of CGMCC No.18744, lactobacillus fermentum LF26 with the preservation number of CGMCC No.19431, lactobacillus helveticus LH43 with the preservation number of CGMCC No.24511, lactobacillus paracasei LPC12 with the preservation number of CGMCC No.24512, lactobacillus rhamnosus LRH10 with the preservation number of CGMCC No.24513 and streptococcus thermophilus ST30 with the preservation number of CGMCC No.24514.
Each capsule contains 150 hundred million Colony Forming Units (CFU).
EXAMPLE 6 Activity assay
1. Experimental objects
There were 31 IBS patients, and three groups were assigned: yoga and placebo group (EC group), yoga and probiotic group (EP group), and probiotic group alone (P group).
Yoga courses were run twice weekly for six weeks; two tablets of AB kefir capsules of example 5 (probiotic supplement, probiotic composition (1.5×10 as main ingredient) were taken daily 10 CFU/grain) for six weeks. Before and after the experiment, the quality of life scale for dysphoria (IBS-QOL), the concise five-symptom rating scale (BSRS-5) and physical fitness test including three-minute stepping test,Sit-extension testing and sit-up testing.
2. Experimental method
Gastroenterologists use roman IV standards and blood tests (including CBC, ESR, and CRP) to rule out non-IBS patients. The study plan was interpreted to the subjects who voluntarily participated in the study. Basic information of the subjects was filled in table 1 before the samples were collected.
TABLE 1 subject basic information
Subjects were randomly assigned to three groups: yoga and placebo group (EC group), yoga and probiotic group (EP group) and probiotic group (P group) for 6 weeks. All subjects had to perform stool sample collection and physical health testing in the laboratory at weeks 0 and 6. The subject also needs to maintain the original lifestyle and eating habits from week 0. The EP group began yoga courses for 6 weeks after initial sampling and testing at week 0. Yoga exercise was performed twice a week for 40 minutes each time with exercise intensity reaching 50-60% of the reserve heart rate (heart rate reserve, HRR). During yoga exercise, the heart rate of the subject was monitored using a heartbeat watch. Meanwhile, the subjects were supplemented with probiotics within six weeks, taking two capsules on an empty stomach before breakfast each day. After initial sampling and testing at week 0, the P groups took two capsules daily on an empty stomach for six weeks before breakfast. The EC group received placebo instead of probiotic supplements and underwent six weeks of yoga exercise.
Placebo capsules are filled with excipients and made into capsules.
3. Collection of physical health test data
The body health assessment is based on the project provided by the taiwan health welfare department of china. These items include body composition (ACCUNIQ, BC300, korea), three-minute stepping (cardiopulmonary function), sit-up test (core muscle group), and sitting extension test (flexibility).
4. Questionnaire
The quality of life scale for irritable bowel disease (IBS-QOL) is a special scale compiled by Patrick et al through literature reviews and clinical interviews with patients suffering from irritable bowel disease. It consists of 34 questions covering 8 areas including mood depression, disturbed activity, physical image, health concerns, food avoidance, social reactions, sex and relationships, etc. The score uses a 5-point scale of line segments reflecting the quality of life of the patient, with a total score ranging from 0 to 100, with higher scores representing better quality of life. This scale reflects well the severity of the disease, as shown by Drossman et al in the IBS-QOL study. IBS-QOL has good sensitivity for evaluating quality of life, and can be used for evaluating curative effect of IBS clinical study.
The Brief Symptom Rating Scale (BSRS) is a mental symptom questionnaire based on depression and anxiety symptoms, wherein the BSRS-anxiety section includes 5 items including anxiety (feeling tension or tension restlessness), depression (feeling depression or low mood), hostility (easy vigilance or dysphoria), interpersonal sensitivity (feeling spell) and other symptoms (difficulty falling asleep in the past week). BSRS-5 is a self-filling questionnaire. The score for each item was from 0 to 4 (0: none at all; 1: slightly, 2: medium, 3: quite, 4: very). A total score of greater than 14 for BSRS-5 may be indicative of a severe mood disorder. A total score between 10 and 14 may represent a moderate mood disorder. A total score between 6 and 9 may represent mild mood disorders. A score below 5 is considered normal.
5. Yoga intervention
Yoga has a long history, which can be traced back to 5000 years ago, and is part of the ancient indian philosophy. Yoga includes posture, respiratory exercise and meditation. The exercise yoga can strengthen muscle strength and reach the balance of body and mind. In recent years, yoga has been used as a motor intervention for the treatment of irritable bowel disease. Results of yoga intervention showed improved symptoms. Yoga exercises in this study were designed for people with little exercise amount at ordinary times. The exercises are divided into a warm-up, a main exercise and a cool-down, for a total of 40 minutes. The warming up takes about five minutes, including breathing exercises and range of motion exercises, including fusion sole push type seats, half fish, cat and cow, etc. The main exercises focus on core muscle training and soft torsion movements, which can improve intestinal motility. The exercises include crawling, single-leg crawling, improved transverse, improved side rest, inverted cicada, abdominal respiration, improved ship and bridge. Cooling for about five minutes helps to extend and relax muscles, including abdominal breathing, pleasurable infant, wind cages, gastric cavity rotation and cadaveric. Breathing exercises have been used for many years to reduce anxiety. There are many studies on how respiration affects physiological and psychological stress. Breathing exercises are performed at the beginning of yoga exercises to enhance concentration and reduce anxiety. There have been some previous studies discussing the relationship between core muscle training, abdominal massage and peristalsis. The results show that these exercises are better for intestinal diseases, especially constipation. Thus, yoga exercises and twisting actions that strengthen the core muscles are selected as self-massage exercises to improve peristalsis. At the end of the exercise, the stretching action is used to relax the muscles and body. The main purpose of this series of yoga exercises is to enhance peristalsis, reduce anxiety and stress.
6. Experimental results
During the period from month 1 of 2021 to month 6 of 2022, a total of 31 subjects were enrolled, with an average age of 38.1±5.7 years, from 1763 patients. Among them, the EC group had 10 persons, the P group had 11 persons, and the EP group had 10 persons. Prior to entering the study, 27 subjects did not conduct physical activity. According to the classification of irritable bowel disease, 8 people belong to IBS-C type, 16 people belong to IBS-D type, and 7 people belong to IBS-M type. Pre-and post-testing analyses were performed on yoga and placebo groups (EC group), yoga and probiotic groups (EP group) and probiotic groups (P group). The experimental results are shown in Table 2.
TABLE 2 results of front and rear measurements
The study analyzed the effects of yoga and probiotic supplements on body composition and performed 3 minutes of physical health testing before and after the study, sit-up testing, sitting-extension testing, and the like. The results of the 3-minute step test showed significant differences between the EP group before and after the study (p < 0.05).
In this study, the effect of yoga and probiotic supplements on subjective questionnaires was analyzed, and six weeks before and after the study. The results of IBS-QOL showed significant differences before and after study of the EP group and the EC group, with p <0.001 for the EP group and p <0.05 for the EC group; but there were no statistical differences in group P. The IBS-QOL scores were lower in all three groups of dysphoric subjects. After the probiotic is supplemented, IBS-QOL scores are improved, and symptoms are relieved. For the results of BSRS-5, there was no significant difference (p > 0.05) between before and after the study in all groups.
In conclusion, yoga exercise and probiotic ingestion can improve the daily life quality of patients with allergic intestinal syndromes and alleviate symptoms. Meanwhile, after six weeks of yoga exercise, the heart and lung functions of the subjects can be effectively improved, and the daily life capacity of the subjects is greatly influenced. Furthermore, yoga or yoga-in combination with probiotic ingestion may be effective to increase the relative proportion of beneficial microbial flora in the gut. This means that it can be a good intervention in the subject and can improve the proportion of dominant species of intestinal microorganisms. As a result, the combination group of yoga exercise combined with probiotic intake had better indicators than single intervention in short term studies.
As described above, although the present invention has been shown and described with reference to certain preferred embodiments, it is not to be construed as limiting the invention itself. Various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (9)
1. A probiotic composition is characterized by comprising bifidobacterium longum BL986 with a preservation number of CGMCC No.18743, lactobacillus acidophilus LA1063 with a preservation number of CGMCC No.18744 and a preservation number of CGMCC
Lactobacillus fermentum LF26 with the preservation number of CGMCC No.24511, lactobacillus helveticus LH43 with the preservation number of CGMCC No.24512, lactobacillus paracasei LPC12 with the preservation number of CGMCC No.24512, lactobacillus rhamnosus LRH10 with the preservation number of CGMCC No.24513, and streptococcus thermophilus ST30 with the preservation number of CGMCC No. 24514;
the ratio of the bacterial numbers of each bacterial strain in the probiotic composition is as follows:
2. the probiotic composition according to claim 1, characterized in that the viable bacterial amount of the composition is not less than 1.5 x 10 10 CFU/g。
3. Use of a probiotic composition according to any one of claims 1-2 for the preparation of a medicament for improving intestinal dryness.
4. Use of a probiotic composition according to any one of claims 1-2 for the preparation of a food or health product for improving intestinal dryness.
5. The use according to claim 3, wherein the probiotic composition significantly improves the effectiveness of yoga intervention or adjuvant therapy during the intervention of yoga for intestinal dryness.
6. A probiotic powder comprising a probiotic composition according to any one of claims 1-2.
7. The method for preparing the probiotic powder according to claim 6, comprising the following steps: separating each strain in the probiotic composition from Taiwan natural dairy kefir grains, preparing freeze-dried powder of each strain by a freeze-drying method, and preparing the probiotic powder by the freeze-dried powder of each strain according to a proportion.
8. The method according to claim 7, wherein the freeze-drying method is a freeze-drying method using maltodextrin and fructooligosaccharides as cryoprotectants.
9. An AB kefir capsule prepared from the probiotic powder of claim 6 and a pharmaceutically acceptable carrier or excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311419265.0A CN117736902A (en) | 2023-10-30 | 2023-10-30 | Probiotic composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311419265.0A CN117736902A (en) | 2023-10-30 | 2023-10-30 | Probiotic composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117736902A true CN117736902A (en) | 2024-03-22 |
Family
ID=90249656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311419265.0A Pending CN117736902A (en) | 2023-10-30 | 2023-10-30 | Probiotic composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117736902A (en) |
-
2023
- 2023-10-30 CN CN202311419265.0A patent/CN117736902A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Makino et al. | Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 | |
| Costalos et al. | Enteral feeding of premature infants with Saccharomyces boulardii | |
| TWI583388B (en) | Use of lactobacillus plantarum for manufacturing anti-fatigue probiotic composition for improve exercise performance | |
| CN111728111A (en) | Probiotic composition for relieving anxiety or depression and application thereof | |
| CN113180109A (en) | Application of lactobacillus reuteri in preparation of products for preventing or treating developmental disorder diseases | |
| RU2725883C2 (en) | Composition for reducing intestinal gas production | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| US10792317B2 (en) | Method for reducing body fat by administering Lactobacillus plantarum | |
| CN111567796A (en) | Sports nutritional probiotic composition and preparation method thereof | |
| KR102606952B1 (en) | Method of Lactobacillus Plantarum TWK10 composition for improving inflammation or reducing body fat after exercise | |
| CN112617207A (en) | A composition containing rehydration salt and probiotic bacteria | |
| CN112515171A (en) | Fluid-supplementing probiotic composition and application thereof | |
| JP6261688B2 (en) | QOL improvement or persistence agent | |
| CN114686405B (en) | Bifidobacterium bifidum with functions of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| US11969447B2 (en) | Use of spray-dried powder derived from lactic acid bacterial strains and herbal extracts for promoting defecation | |
| CN117736902A (en) | Probiotic composition and application thereof | |
| US20230112367A1 (en) | Probiotic compositions for improving human health and athletic performance | |
| WO2022196488A1 (en) | Composition for improving qol | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN115466687B (en) | Composition for reducing body fat content and body weight and application thereof | |
| US20240139262A1 (en) | Complex probiotic composition and method for improving exercise performance of subject with low intrinsic aerobic exercise capacity | |
| CN110384719B (en) | Lactobacillus reuteri strain GMNL-263 capable of improving hypertension and composition thereof | |
| US20200188453A1 (en) | Method of a lactobacillus plantarum twk10 composition for improving inflammation after exercise | |
| US20190388484A1 (en) | Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof | |
| CN114053342A (en) | Composition for promoting defecation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |